HC Wainwright Reiterates “Buy” Rating for Humanigen (NASDAQ:HGEN)

Humanigen (NASDAQ:HGEN)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They presently have a $36.00 target price on the stock, up from their previous target price of $34.00. HC Wainwright’s target price points to a potential upside of 165.88% from the company’s current price.

HGEN has been the subject of a number of other reports. National Securities started coverage on Humanigen in a research report on Wednesday, December 23rd. They set a “buy” rating and a $35.00 price objective for the company. Zacks Investment Research raised Humanigen from a “sell” rating to a “hold” rating in a research report on Friday, March 12th. Roth Capital raised their price objective on Humanigen from $25.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday, March 29th. JPMorgan Chase & Co. initiated coverage on Humanigen in a research report on Tuesday, February 23rd. They set a “neutral” rating and a $21.00 price objective for the company. Finally, Jefferies Financial Group initiated coverage on Humanigen in a research report on Tuesday, December 22nd. They issued a “buy” rating and a $27.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $29.83.

Shares of HGEN opened at $13.54 on Monday. Humanigen has a 52-week low of $3.87 and a 52-week high of $33.95. The stock has a fifty day simple moving average of $16.45 and a two-hundred day simple moving average of $16.58.

Humanigen (NASDAQ:HGEN) last issued its earnings results on Tuesday, March 9th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.04. The company had revenue of $0.31 million during the quarter. On average, sell-side analysts forecast that Humanigen will post -2.13 EPS for the current fiscal year.

In other news, major shareholder Bay Ltd. Nomis sold 23,140 shares of Humanigen stock in a transaction dated Monday, January 25th. The stock was sold at an average price of $19.23, for a total value of $444,982.20. Following the completion of the transaction, the insider now owns 6,093,140 shares in the company, valued at approximately $117,171,082.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 484,920 shares of company stock valued at $9,177,741 in the last quarter. Company insiders own 37.50% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. boosted its stake in shares of Humanigen by 12.8% in the 4th quarter. BlackRock Inc. now owns 790,602 shares of the company’s stock valued at $13,836,000 after buying an additional 89,662 shares during the period. Charles Schwab Investment Management Inc. purchased a new stake in Humanigen during the fourth quarter worth approximately $3,270,000. tru Independence LLC purchased a new stake in Humanigen during the fourth quarter worth approximately $2,700,000. M Holdings Securities Inc. lifted its stake in Humanigen by 11.8% during the fourth quarter. M Holdings Securities Inc. now owns 109,900 shares of the company’s stock worth $1,923,000 after purchasing an additional 11,600 shares during the last quarter. Finally, Northern Trust Corp purchased a new stake in Humanigen during the fourth quarter worth approximately $1,295,000. Institutional investors and hedge funds own 30.18% of the company’s stock.

About Humanigen

Humanigen, Inc, a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which is in Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that has completed Phase I clinical trial in patients with chronic myelomonocytic leukemia.

Recommended Story: What is an overbought condition?

Analyst Recommendations for Humanigen (NASDAQ:HGEN)

Receive News & Ratings for Humanigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humanigen and related companies with MarketBeat.com's FREE daily email newsletter.